FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Verdict

Headline leans bullish. We score OMER +1.00 across two claims.

Score confirms the headline.

Headline says

Leans bullish

From its wording — no explicit rating

=

Expected · OMER

+1.00strongly bullish